KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Change in Account Payables (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Change in Account Payables for 5 consecutive years, with -$47.1 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Change in Account Payables fell 5.78% year-over-year to -$47.1 million, compared with a TTM value of $12.2 million through Mar 2025, up 353.57%, and an annual FY2025 reading of $57.8 million, up 291.19% over the prior year.
  • Change in Account Payables was -$47.1 million for Q1 2025 at Biocryst Pharmaceuticals, down from $74.7 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $74.7 million in Q4 2024 and bottomed at -$47.1 million in Q1 2025.
  • Average Change in Account Payables over 3 years is -$2.2 million, with a median of -$9.3 million recorded in 2023.
  • Peak annual rise in Change in Account Payables hit 69.45% in 2024, while the deepest fall reached 6567.02% in 2024.
  • Year by year, Change in Account Payables stood at $49.2 million in 2023, then surged by 51.82% to $74.7 million in 2024, then tumbled by 163.1% to -$47.1 million in 2025.
  • Business Quant data shows Change in Account Payables for BCRX at -$47.1 million in Q1 2025, $74.7 million in Q4 2024, and -$2.8 million in Q3 2024.